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ABSTRACT 
There is a growing interest towards the development of new antibiotics from last decades due to emergence of newer pathogenic bacterial strains 
with high resistance to powerful antibiotics of last resort. This has caused decline in research for developing newer antibacterial agents. Hence, 
there is continuous need to develop newer antibiotics that interact with essential mechanisms in bacteria. Recently, enzymes responsible for bio 
synthesis of the essential amino acid lysine in bacteria have been targeted and it has augmented interest to develop novel antibiotics and to enhance 
lysine yields in over-producing organisms. Peptidoglycan layer consists of a beta-1,4-linked polysaccharide of alternating N-acetylglucosamine 
(NAG) and N-acetylmuramic acid (NAM) sugar units, cross linked by short pentapeptide (muramyl residues) side chain of general structure L-Ala-g-
D-Glu-X- D-Ala-D-Ala, where X is either L–Lysine or meso-DAP. Formation of the cross-links makes bacterial cell wall resistant to lysis by 
intracellular osmotic pressure. Compounds which inhibit lysine or DAP biosynthesis could therefore be very effective antibiotics and novel targets. 
Lysine is a constituent in gram-positive bacteria while meso-DAP occurs in gram negative ones. In this review, substrate-based inhibitors of 
enzymes in the DAP pathway and inhibitors that allow better understanding of enzymology of the targets and provide insight for design of new 
inhibitors have been discussed. Resistant bacterial strains can be inhibited by using synthetic enzyme inhibitors of DAP pathway that are less toxic 
to mammals. Newer antimicrobial drugs can be thus developed by targeting the enzymes involved in this pathway. 
Keywords: L-lysine, Antimicrobial resistance, Diaminopimelic acid, Enzyme inhibitors, Diaminopimelate epimerase.  
 
INTRODUCTION 
Literally, the word ‘antibiotic’ refers to the compound that opposes 
life and typically antibacterial drug is the one which interferes with 
the structures or processes essential for the growth or survival of 
microorganisms. Today, antibiotic resistance is widespread and ever 
increasing. Hence, there is a need to continuously develop newer 
antibacterial agents which shall combat with the bacterial survival 
strategies. However, clinically significant antibacterial resistance 
develops in periods of few months to years. For penicillin resistance, 
the phenomenon was noted within two years after introduction of 
penicillin in the mid 1940s [1-3].  
A serious attention in the search for novel antibacterial compounds 
has developed due to the recent emergence of mutated bacterial 
strains resistant to currently available antibiotics. These compounds 
should be targeted toward biomolecules that are essential for 
bacterial viability but are absent in mammals [4, 5]. Both of these 
criteria are met by the diaminopimelic acid (DAP) and lysine 
biosynthesis pathway, thereby presenting multiple targets for novel 
antimicrobial agents [6, 7]. Lysine is an essential amino acid 
required in protein synthesis and is also a constituent of the 
peptidoglycan layer of cell walls in gram positive bacteria. The lysine 
biosynthesis also produces D,L-DAP, (meso-DAP), which is a 
component of the peptidoglycan layer of gram negative bacteria and 
mycobacterial cell walls (Figure 1a). This review focuses on current 
research which is being carried out on structure-based drug 
discovery of antimicrobial drugs [8, 9]. DAP is a symmetrical α,α-
diaminodicarboxylic acid and exists in three stereoisomeric forms as 
shown in (Figure 1b).  
Among these, meso-DAP and (S,S)-DAP and serve as the precursors 
in the biosynthesis of L-lysine [10]. Peptidoglycan layer consists of a 
beta-1,4-linked polysaccharide of alternating N-acetylglucosamine 
(NAG) and N-acetylmuramic acid (NAM) sugar units as building 
blocks of cell wall. Attached to the lactyl side chain of NAM unit is a 
pentapeptide (muramyl residues) side chain of general structure L-
Ala-g-D-Glu-X- D-Ala-D-Ala, where X is either L–Lysine or meso-DAP 
[11-13]. Formation of the cross links makes the bacterial cell wall 
resistant to lysis. Compounds which inhibit lysine or DAP 
biosynthesis could therefore be very effective antibiotics, if targeted 
towards cell wall biosynthesis. The enzymes which catalyze the 
synthesis of L-lysine in plants and bacteria have attracted interest 
from two directions; firstly from those interested in inhibiting lysine 
biosynthesis as a strategy for the development of novel antibiotic or 
herbicidal compounds and secondly to enhance lysine yields in over-
producing organisms. Certain advances in genetic studies have also 
permitted the researchers to compare protein sequences from many 
dissimilar organisms and has ultimately resulted in cloning of the 
biosynthetic genes and their over expression [14]. More than 
hundred tons of L-lysine are produced annually with C. glutamicum 
mutant strains. Genes directly involved in the synthesis of L-lysine 
are primary targets to improve the overall fermentation process. C. 
glutamicum genome sequencing has been identified and 
characterized, dapF and dapC genes have showed significant effects 
on L–lysine production when over expressed in C. glutamicum strain 
[15]. Many biological effects such as cytotoxicity, antitumor 
activities, angiotensin converting enzyme (ACE) inhibitory, 
immunostimulant and sleep-inducing effects are shown by a range 
of peptidoglycan monomers such as the potent toxin from B. 
pertussis and N. gonorrhoeae and similar DAP containing peptides 
[16-18].  
Lysine biosynthetic pathway in bacteria 
The synthesis of lysine begins with the phosphorylation of L-
aspartate to form L-aspartylphosphate catalyzed by aspartate 
kinase. Both B. subtilis and E. coli genomes encoding show three 
aspartokinase isozymes, required for different biosynthetic 
pathways starting from aspartate. E. coli has two bifunctional 
aspartokinase/homo-serine dehydrogenases, ThrA and MetL, and a 
monofunctional aspartokinase LysC, which are involved in the 
threonine, methionine and lysine synthesis; respectively. 
Transcription of the aspartokinase genes in E. coli is regulated by 
appropriate concentrations of the corresponding amino acids. In 
addition, ThrA and LysC are feedback inhibited by threonine and 
lysine; respectively [19,20]. Aspartate semialdehyde dehydrogenase 
converts the L-aspartylphosphate to aspartate semialdehyde. The 
first two steps of the DAP pathway are catalyzed by aspartokinase 
and aspartate semialdehyde dehydrogenase are common for the 
biosynthesis of amino acids of the aspartate family, like lysine, 
threonine and methionine [21]. Dihydrodipicolinate synthase 
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28 
catalyses the condensation of pyruvate (PYR) and aspartate 
semialdehyde (ASA) to form 4-hydroxy-2,3,4,5-tetrahydro-L,L-
dipicolinic acid (HTPA). This enzyme belongs to the family of lyases, 
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Fig. 1: (a) Peptidoglycan structure with peptide cross-linking in gram positive and gram negative bacteria. (b) Stereoisomers of 
diaminopimelic acid (DAP). 
 
Fig. 2: Enzymes of the lysine biosynthesis in bacteria operating through acetylase, succinylase and aminotransferase pathways
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The studies using [13]C-labelled pyruvate demonstrate that the 
product is the unstable heterocycle HTPA. Rapid decomposition of 
the [13]C-NMR signals of HTPA following its production indicates 
that formation of L-dihydrodipicolinate (DHDP) occurs via a 
nonenzymatic step. Dihydrodipicolinate reductase (DHDPR) 
catalyses the pyridine nucleotide-dependent reduction of DHDP to 
form L-2,3,4,5,-tetrahydrodipicolinate (THDP). THDP and DHDP are 
synthesized from aspartate semialdehyde by the products of the 
dapA and dapB genes (Figure 2). However, the metabolic pathway 
then diverges into three sub-pathways depending on the species, 
namely the succinylase, acetylase and aminotransferase pathways 
from tetrahydrodipicolinate in bacteria. The presence of multiple 
biosynthetic pathways is probably a result of the importance of DAP 
and lysine to bacterial survival [23]. The most common of the 
alternative metabolic routes is the succinylase pathway, which is 
inherent to many bacterial species including E. coli This sub-
pathway begins with the conversion of tetrahydrodipicolinate to N-
succinyl-L-2-amino-6-ketopimelate (NSAKP) and is catalyzed by 
2,3,4,5-tetrahydropyridine-2-carboxylate N-succinyltransferase 
(dapD, THPC-NST). NSAKP is then converted to N-succinyl-L,L-2,6,-
diaminopimelate (NSDAP) by N-succinyldiaminopimelate 
aminotransferase (DapC, NSDAP-AT). Subsequently, it is 
desuccinylated by succinyldiaminopimelate desuccinylase (dapE, 
SDAP-DS) to form L,L-2,6-diaminopimelate (LL-DAP). The acetylase 
pathway also involves four enzymatic steps, but incorporates N-
acetyl groups rather than N-succinyl moieties. This pathway is 
common to several bacillus species, including B. subtilis and B. 
anthracis [24]. The succinylase pathway is utilized by all gram 
negative and many gram positive bacteria, while the acetylase 
pathway appears to be limited to certain bacillus species. There is 
one additional sub-pathway which is less common to bacteria which 
is called as the aminotransferase pathway This is catalyzed by the 
enzyme diaminopimelate aminotransferase (LL-DAP-AT) which 
transforms L-tetrahydrodipicolinic acid (L-THDP) directly to LL-
DAP. Accordingly, after the formation of L,L-DAP, which is common 
in all three pathways, the enzyme L,L-diaminopimelate epimerase 
(DAPE, dapF) catalyzes the epimerization of L,L-DAP to form meso-
DAP. All alternative pathways then converge to utilize the same 
enzyme for the final step of lysine biosynthesis, namely 
diaminopimelate decarboxylase (DAPDC, LysA) which catalyses the 
decarboxylation of meso-DAP to yield lysine and carbon dioxide. 
This step is important for the overall regulation of the lysine 
biosynthesis. Comparative analysis of genes and regulatory elements 
identify the lysine-specific RNA element, named as the LYS element, 
in the regulatory regions of bacterial genes which are involved in 
biosynthesis and transport of lysine. The LYS element includes 
regions of lysine-constitutive mutations previously identified in E. 
coli and B. subtilis.The lysine biosynthetic pathway has a special 
interest for pharmacology, since the absence of DAP in mammalian 
cells allows for the use of the lysine biosynthetic genes as a bacteria-
specific drug target. 
This review describes the essential details of the key enzymes 
functioning in the lysine biosynthetic pathway. Enzymes of this 
pathway are the products of essential bacterial genes that are not 
expressed in humans. The pathway is of interest to antibiotic 
discovery research. Accordingly, it also gives the current status of 
rational drug design initiatives targeting essential enzymes of the 
lysine biosynthesis pathway in resistant strains of pathogenic 
bacteria. More recently, cloning and expression of the DAP pathway 
components has facilitated detailed investigations and structures of 
the enzymes have been determined by X-ray crystallography [25]. 
Succinylase pathway  
Tetrahydrodipicolinate N-succinyltransferase (THPC-NST, EC 
2.3.1.117, dapD)  
The crystal structure of THPC-NST from M. bovisat 2.20A resolution 
revealed a trimeric structure with each protomer consisting of three 
domains: α-helical N-terminal domain, α,β-sheet C-terminal domain 
and a distinctive β-helix middle domain. THPC-NST is the the 
essential gene product of dapD and this enzyme is a member of the 
hexapeptide acyltransferase superfamily, the enzymes containing 
repeated copies of an imperfect hexapeptide sequence, (LIV)-
(GAED)-X2-(STAV)-X (in single letter code for amino acids, denote 
alternative amino acids at the position, X indicates any amino acid). 
Crystal structures with bound substrates and CoA have identified 
the active site of an enzyme located at the interface between two 
left-handed parallel β-helices (LβH) of the trimeric enzyme. 
Comparison with the structure of the apoenzyme from M. bovis and 
E. coli reveals the C-terminus of the enzyme forms an α-helix, which 
blocks the CoA binding site. Upon binding to CoA, this helix moves 20 
A to participate in substrate binding. Structure of the E. coli, M. bovis 
and Mtb-DapD reveal the different orientation and conformational 
changes responsible for the cooperative binding of CoA and 
substrate by the enzyme [26]. Electron density maps around the 
active site glutamate Glu199 might be interpreted as evidence for a 
covalent reaction intermediate between the succinyl group of the 
cofactor and the carboxylate side chain of the glutamate. Finally, Mtb-
DapD shows water-filled channel systems, which allow access to the 
metal ions bound between the three molecules of the trimer [27]. 
N-Succinyl- L,L-diaminopimelate aminotransferase (NSDAP-AT, 
EC 2.6.1.17, dapC) 
NSDAP-AT catalyzes the transfer of an amino group from L-
glutamate to NSAKP to generate NSDAP. NSDAP-AT is a family of 
class I PLP-dependent aminotransferase, which exists as a 
homodimer (in M. tuberculosis NSDAP-AT). The reaction begins by 
the formation of a Schiff base linkage between an active site lysine 
and the cofactor pyridoxal-5’-phosphate (PLP). The gene encoding 
NSDAP-AT (dapC), is found in a large number of bacterial species 
including Bordetella pertussis, C. glutamicum, E. coli, and M. 
tuberculosis. In E. coli, the gene encoding NSDAP-AT is annotated arg 
D. The dapC gene in B. pertussis, C. glutamicum, and E. coli has been 
found to map in close proximity to the dapD gene on the 
chromosome. Sequence analyses have shown that NSDAP-AT 
consists of approximately 400 residues and shares greater than 26% 
identity across species. The monomer subunit is comprised of an α-
helical N-terminal extension and central domain comprising an 8 
stranded β-sheet surrounded by 8 α-helices, and a C-terminal 
domain consisting of a four stranded β-sheet flanked by 4 α-helices. 
The active site of each subunit is located at the dimer interface with 
residues from both subunits contributing to the architecture of the 
active sites. PLP is bound to the active site Lys232, presumably via a 
Schiff base, and makes a number of noncovalent contacts with other 
residues within the active site via a hydrogen bond network. The 
predicted DapC protein of C. glutamicum shared 29% identical 
amino acids with DapC from B. pertussis. However, overexpression 
of the dapC gene in C. glutamicum resulted in a 9-fold increase of the 
specific aminotransferase activity [38]. Many substrate analogues 
(Figure 4) of NSDAP-AT have synthesized with different N-acyl 
substituents. DAP-AT has quite strict requirements for substrate 
recognition, But it will accept compounds with an aromatic ring in 
place of the terminal succinyl carboxyl group in 4a. the compound 5a 
and 5b hydrazine analogues are the most potent slow-binding 
inhibitors NSDAP-AT enzyme reported so far [29]. Dipeptide 
substrates of DAP-AT have prepared as hydrazines analogues 6 and 
7. The hydrazino-dipeptides showed potent slow binding inhibition 
of DAP-AT from E. coli. Biological activity of these synthetic peptides 
is a longer term strategy to develop peptide libraries and peptide-
mimetics. DAP-AT has been shown to be a suitable target for the 
development of novel antimicrobial compounds [30, 31]. 
N-Succinyl-L,L-diaminopimelic acid desuccinylase (E. C. 
3.5.1.18, SDAP-DS, dapE) 
SDAP-DS catalyzes the hydrolysis of NSDAP to form L,L-DAP. The 
enzyme requires a divalent metal ion for activity, preferably zinc or 
cobalt and has sequence similarity to a number of other metal-
dependent enzymes, A molecular size of 43 kDa [32]. The gene 
encoding SDAP-DS, dapE is present in a large number of bacterial 
species including, M. tuberculosis, E. coli, Y. pestis, V. cholerae, H. 
pylori, H. influenzae, S. aureus and many more. The fact that the DapE 
gene has been discovered in several multi-drug-resistant bacteria 
suggests that inhibitors of DapE enzymes may provide a new class of 
broad-spectrum antibiotics. Alignment of the DapE proteins listed 
above show a minimum of 49% sequence Identity across bacterial 
species. The SDAP-DS amino acid sequences show conservation of 
Kale et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 10, 27-35 
 
30 
histidine and glutamate metal binding residues that are 
characteristic of metal-dependent amidases. It is hypothesised that 
NSDAP adopts an extended conformation when bound to the active 
site of the enzyme. The NSDAP amide carbonyl coordinates to an 
active site Zn2+ ion and becomes avaliable for nucleophilic attack. 
This binding event displaces a bridging water molecule, resulting in 
its hydrolysis by Glu134 and the generation of a zinc bound 
nucleophilic hydroxide. The hydroxide then attacks the target 
carbonyl carbon to form a η-1-μ-transition-state complex, which 
then resolves to release DAP and succinate. The crystal structure of 
zinc bound SDAP-DS shows that the enzyme forms a homodimer, 
with each monomer subunit containing a catalytic domain and a 
dimerisation domain. The core of the catalytic domain is composed 
of an eight-stranded twisted β-sheet that is sandwiched between 
seven α-helices. The dimerisation domain adopts a two layer α+β 
sandwich fold and is comprised of a four stranded antiparallel β-
sheet and two α-helices [33]. A screen biased toward compounds 
containing zinc-binding groups (ZBG’s) including thiols, carboxylic acids, 
boronic acids, phosphonates and hydroxamates has delivered a number 
of micromolar inhibitors of DapE from H. influenzae, including the low 
micromolar inhibitor L-captopril (IC 50 = 3.3l M, IC50 = 1.8l M). In vitro 
antimicrobial activity was demonstrated for L-captopril against E. coli. 
Boronic acid tested as inhibitors of DapE [34, 35]. 
Aminotransferase pathway  
Function of diaminopimelate aminotransferase (LL-DAP-AT, EC 
2.6.1.83, DapL): LL-DAP-AT is a PLP-dependant enzyme that 
catalyses the conversion of L-2,3,4,5,-tetrahydrodipicolinate (THDP) 
to LL-DAP (Figure 3). This transamination reaction utilises 
glutamate as an amino donor to yield A-ketoglutarate. Studies of 
crude cell extracts have shown that plants do not catalyse reactions 
specific to the succinylase, acetylase or dehydrogenase pathway 
[36]. This confirmed that annotated plant genomes, including A. 
thaliana, lack some or all genes associated with the three classical 
pathway [37]. Bacteroides fragilis and Clostridium thermocellum 
were recently found to synthesize diaminopimelate (DAP) by way of 
LL-DAP aminotransferase. Both species also contain an ortholog of 
meso-diaminopimelate dehydrogenase (Ddh), suggesting that they 
may have redundant pathways for DAP biosynthesis. Analysis of the 
microbial genome database revealed that 77% of species with a Ddh 
ortholog also contain a second pathway for DAP biosynthesis 
suggesting that Ddh evolved as anancillary mechanism for DAP 
biosynthesis [38]. The phylogenenetic study of LL-DAP-AT from 
defferent species shows the existence of two classes of LL-DAP-AT 
orthologues, namely, DapL1 and DapL2, which differ significantly in 
primary amino acid sequence. DapL1 and DapL2 are found 
predominantly in eubacteria and archaea, respectively. LL-DAP-AT 
has 20% sequence identity when compared to bacterial NSDAP-AT 
(Dap C)[40] LL-DAP-AT enzymes from plants and Chlamydia belong 
to the Dap L1 variant of LL-DAP-AT and share approximately 50% 
amino acid sequence identity. The DapL 2 variant is primarily found 
in Archaea and shares approximately 30% amino acid sequence 
identity with the DapL 1 variant.[41] LL-DAP-AT enzymes are 
classified as members of the PLP-dependant protein superfamily of 
class I/II aminotransferases It is reported that C. trachomatisand and 
P. amoebophila also use the LL-DAP-AT pathway, there by 
supporting an evolutionary relationship between cyanobacteria and 
Chlamydiales. Chlamydia Species that can cause pneumonia [39,40] 
urinary tract infections, sexually transmitted infections and may be 
involved in coronary heart disease [41-43]. 
Structure of LL-DAP-AT 
The crystal structure of LL-DAP-AT from different species like A. 
thaliana, C. trachomatis and M. tuberculosis (Mtb) has been 
identified. LL-DAP-AT-Mtb is active as a homodimer with each 
subunit having PLP in the active site [44]. The crystal structure of 
LL-DAP-AT consists of two domains, the large domain (LD) and the 
small domain (SD) (Figure 3). The LD (Asn48 to Gln294) consists of 
246 amino acid residues and folds into an α–β–α sandwich. This 
domain acts as the PLP binding scaffold and is involved in the 
majority of the dimer-forming inter actions. The SD (Met1 to Leu4 7 
plus Leu29 5 to Ser394) consists of the N-terminal arm region and 
the last 100 residues of the C-terminus and this domain forms an α–
β complex. The active site is situated in a groove between the two 
domains of the monomer (Figure 3). Structural Study of the apo and 
ligand-bound forms of C. trachomatis LL-DAP-AT have revealed that 
the enzyme adopts an open and closed conformation [45]. In the 
absence of ligand, the enzyme assumes an open state, whereby the 
active site is exposed to solvent. Upon PLP binding, the enzyme 
adopts a closed conformation. Within the active site, PLP is 
covalently linked to Lys236 via a Schiff base and is stabilized 
through an aromatic stacking interaction with Tyr128. PLP also 
forms a network of hydrogen bonding interactions with residues 
within the enzyme active site.  
 
Fig. 3: The overall structure of the Mtb-DAP-AT homodimer. 
One monomer is represented in red, the other monomer in 
grey. The PLP moieties are represented as ball-and-stick 
models and the bound chloride ions as yellow spheres 
 
Inhibition of LL-DAP-AT 
Recently 29,201 inhibitors were screened against LL-DAP-AT. An 
aryl hydrazide and rhodanine derivatives were further modified to 
generate analogues that were also tested against LL-DAP-AT [46] 
the screening of a compound library against LL-DAP-AT identified 
an o-sulfonamido-arylhydrazide (12) as a reversible inhibitor with 
IC50 = 5μM, which is derived from the compound (10) (Figure 4). 
The best inhibitor 34, interact directly with PLP through its free 
amino group. Compound (12) is selected as lead compound for 
further development. Structure–activity relationships (SAR) studies 
based on this lead compound identified key structural features 
essential for enzyme inhibition and to slightly improved inhibitors. 
By using SAR study, 16 hydrazide analogues were synthesized based 
on a lead compound (12). The analogues were tested as inhibitors 
against LL-DAP-AT from A. thaliana as shown in (Figure 4, 
compound 10-24) only a few hydrazide analogues were showing 
promising result. The best inhibitor was found to be an o-
sulfonamido-p-fluorophenyl hydrazide (16), with an IC50 value of 
2.5 μM [47]. The rhodanine-based inhibitor (9) contains rhodanine ring 
with furan ring derivative attached, which was chosen as lead compound 
for SAR studies. It shows that the substituent on the nitrogen has little 
effect on the activity of these inhibitors, whereas the presence of an 
electron-donating group on the aromatic ring enhances activity. Both 
types of inhibitors are still far from becoming effective antimicrobial 
agents at this point. Future investigations of inhibitors together with 
structural studies of LL-DAP-AT will be important in developing novel 
antibiotics targeting LL-DAP-AT. 
Diaminopimelate epimerase (DAPE, EC 5.1.1.7, dapF gene) 
Function of DAPE 
DAPE catalyses the conversion of L,L-2,6-diaminopimelate (LL-DAP) 
to meso-DAP. meso-DAP immediate precursor of lysine in the lysine 
biosynthesis. DAPE is encoded by the dapF gene [48]. DAPE was first 
characterized in 1957 using enzyme derived from crude extracts of 
E. coli. The enzyme specifically recognizes the LL-DAP isomer, 
whereas the DD-DAP isomer is not a substrate or inhibitor of the 
enzyme. Early studies noted that DAPE was inhibited by low 
concentrations of thiol-binding reagents and could be reactivated by 
reducing agents, suggesting the presence of an essential sulfhydryl 
group. This finding was subsequently confirmed upon purification of 
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X = O ,  R = H          (35a)
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Fig. 4: Substrate-based analogs of enzymes involve in lysine biosynthesis 
 
Mechanism of conversion LL-DAP to meso-DAP 
DAPE catalyses the conversion of LL-DAP (37) to meso-DAP (38) by 
employing a “two-base” mechanism.[49, 50] The reaction involves 
two active site cysteine residues Cys73 and Cys217, whereas first 
Cys73 thiolate (73 in H. influenzae) acts as base abstracting proton 
from LL-DAP, while the second Cys217 thiol (217 in H. influenzae) 
reprotonates the molecule the resulting planar carbanionic 
intermediate (39) from the opposite side to generate meso-DAP 
(Figure 5). Epimerization reaction of L,L-DAP at neutral pH causes 
these cysteines to exist as a rapidly equilibrating thiolate–thiol pair 
in the presence of the substrate.  
The stereoinversion involves two active-site cysteine residues acting 
in concert as a base (thiolate) and an acid (thiol). Formation of a 
rigidly held thiolate–thiol pair from the two cysteines in the active 
site with exclusion of solvent enhances basicity for removal of the α-
hydrogen [51]. The two catalytic residues Cys73 and Cys217 have 
been confirmed by DFT quantum mechanical computation of the 
Michaelis complex. All this mechanistic information could be useful 
for the rational design of new potential antibiotic drugs effective as 
inhibitors of peptidoglycan biosynthesis. 
Structure of DAPE 
The structures of DAPE from four species have been described these 
include DAPE from B. anthracis, H. influenza, M. tuberculosis and also 
from the plant species A. thaliana. The crystal structures of the apo-
forms of DAP epimerase mutants (C73S and C217S) from H. 
influenzae at 2.3 A˚ and 2.2 A˚ resolution, respectively. These 
structures provide a snapshot of the enzyme in the first step of the 
catalytic cycle. DAPE adopts two distinct conformational states. In 
the absence of substrate, the enzyme exists in an open conformation, 
and upon binding substrate adopts a closed conformation. The ‘open 
conformation’ of the enzyme prior to substrate binding provide a 
significant new tools for the rational design and discovery of novel 
Kale et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 10, 27-35 
 
32 
inhibitors of this important protein drug target.DAP epimerase has 
symmetrical monomer comprised of two domains with residues 1–
117 and 263–274 forming the N-terminal domain and residues 118–
262 forming the C-terminal domain; each containing eight β-strands 
and two-α helices and each domain contributing one active-site 
cysteine (Figure 6). The DAP epimerase from plants like A. thaliana 
has approximately same structure to the enzyme from bacteria (H. 
influenzae) and shares a similar mechanism [52]. 
The residues lining the active-site cavity are largely conserved 
across all of the DAP epimerase sequences isolated from different 
bacterial species and include: Asn-11, Phe-13, Gln-44, Ty r-60, Asn-
64, Val-70, Glu-72, Cys-73, Gly-74, Asn-75, Asn-157, Asn-190, Glu-
208, Arg-209, Cys-217, Gly-218, and Ser-219. Some of these residues 
in the inhibitor bound enzyme form an extensive hydrogen-bonded 
network surrounding the inhibitor. Electron density maps and 
crystal structure study revealed the location of the two 
diastereomeric inhibitors LL-aziDAP (40) and DL-aziDAP (41) in the 
active site of DAP epimerase (Figure 5), the carboxyl group at the 
distal site of both inhibitors (40 & 41) forms a salt bridge with the 
positively charged side chain of Arg-209 along with three hydrogen 
bonds from side chain Nδ2 atoms of residues Asn-64, Asn-157, and 
Asn-190. The distal positively charged amino group of the inhibitors 
forms three hydrogen bonds with side-chain oxygen atoms of Asn-
64 and Glu-208 and the carbonyl oxygen of Arg-209. The 
asymmetric disposition of side chains of Asn-64 and Asn-157 
situated on opposite sides of the C-6 carbon of the inhibitor, coupled 
with tight packing of other active-site residues surrounding the 
distal site, prevents the binding of a D-isomer at that position.  
The binding interactions of the distal L-stereocenter of LL- and DL-
aziDAP help in positioning the substrate carbon skeleton correctly 
for forming the covalent bond from the cysteine sulfur and the 
methylene carbon of aziDAP. LL-Azi-DAP (40) selectively binds to 
Cys-73 of the enzyme active site whereas DL-azi-DAP (41) binds to 
Cys-217 via attack of sulfhydryl on the methylene of the inhibitor 
aziridine ring. The binding of the aziDAP inhibitors to DAP 






















































Fig. 5: (A) Epimerization reaction of L,L-diaminopimelic acid (DAP).(B) Inhibition of dap-epimerase by L,L-azi DAP and D,L-aziDAP.[51,52] 
 
 
Fig. 6: Ribbon diagram of DAP epimerase from A. thaliana. The 
two domains (shown in green and yellow), and the substrate-
mimic inhibitor AziDAP (spheres; magenta) is bound at the 
active site located in a cleft between the two domains [54]. 
 
Substrate requirement for DAPE  
Enzyme inverts the configuration at the α-carbon of an amino acid 
under physiological conditions without the assistance of any metal 
ions or cofactors. Recently crystal structures of some of the bacterial 
PLP-independent racemases including glutamate racemase, 
aspartate racemase, prolineracemase, and DAPE resolved but DAPE 
differs from these latter racemases, because it can discriminate 
between two stereocentres. The docking of the ligand–enzyme 
complex was studied by means of MD simulations and DFT 
computations in order to ascertain the optimal structural 
requirements for the epimerization reaction. MD simulations study 
shows that the configuration of the distal carbon C–6 of L,L-DAP is 
critical for complex formation since both amino and carboxylate 
groups are involved in H–bonding interactions with the active site 
residues. The interactions occurring between the functional groups 
bonded to the C–2 and some residues of the binding cavity 
immobilize the ligand in a position appropriate for the epimerization 
reaction, i. e. exactly in the middle of the two catalytic residues 
Cys73 and Cys217 as confirmed by DFT quantum mechanical 
computation of the Michaelis complex. Specific interactions at the 
distal site requires only L-configuration. The enzyme discriminates 
between these two stereocenters and interconverts LL-DAP and DL 
(meso)-DAP, but it cannot further epimerize DL-DAP to DD-DAP. 
 This shows D,D-DAP is neither a substrate nor inhibitor for this 
enzyme, Supporting the hypothesis and experimental evidences that 
the stereochemistry of the non-reacting (distal) C–6 carbon is 
critical for ligand recognition or activity. DAP analogs lacking an 
amino or carboxyl group are neither substrates nor effective 
inhibitors [53]. 
Substrate-based inhibitors of DAPE 
These have been developed by using the computational and rational 
drug design (Figure 4). These analogs show time dependent 
competitive and non-competitive inactivation of the enzyme as 
antibacterial activities. Hydroxylated and halogenated analogues of 
LL-DAP have tested against DAPE. The hydroxylated Compounds 
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(27b) proved to be very weak inhibitors of DAPE with 50% 
inhibition. The fluoro analogues (27a) of L,L-DAP, were potent 
competitive inhibitors of DAPE (IC50 = 4-25 pM). the carbon bearing 
fluorine, undergoes rapid epimerase-catalyzed elimination of 
hydrogen fluoride without detectable epimerization [54-56]. 
Heterocyclic analogues of DAP like oxazole, imidazole isoxazole, 
aziridine has DAPE inhibitory activity azi-DAP (36) have been 
shown to be a irreversible inhibitor of DAPE with an IC50 value of 
2.88 mM [57-59].  
Recently the oxa analogues of azi-DAP was found to irreversibly 
inhibit DAP epimerase, presumably due to thiol opening of the 
epoxide moiety. The series of phosphonic acid analogues of this 
diamino-dicarboxylic acid is synthesized, mono-(32) and 
diphosphonic acid derivatives (33) as well as their homologues, N-
alkyl analogues, A phenylphosphinic derivative (34) and some 
peptidyl derivatives. All the prepared compounds were tested for 
their antibacterial activity [60, 61]. 4-Oxa-2,6-diaminopimelic acid 
35a (oxa-DAP) and its methyl-substituted derivatives 35b and 
orthogonally protected lanthionine analogues of DAP (lanthionine-
DAP) and β-methyllanthionine wherein central oxygen replaces 
sulfur were prepared. Oxa-DAP and lanthionine-DAP is a substrate 
of DAPE [62, 63]. A series of di- and tripeptides of individual P-DAP 
isomers with L-alanine were synthesized to enhance transport into 
bacterial cells for antimicrobial tests [64, 65]. Possible mechanisms 
of epimerase inhibition and significance of the DAP pathway as a 
target for antibiotics are discussed. 
CONCLUSION 
The review explores the existing chemical analogs possessing 
antibacterial activity through enzyme inhibition and draws the need 
to further develop newer chemical analogs especially by exploiting 
lysine biosynthetic pathway. It reflects the necessity to develop such 
analogs to combat with the mutated and resistant bacteria.  
These analogs will be target oriented and in a small concentration, 
will restrain the proteins and enzymes that are mandatory for the 
survival of bacteria. Such newer antibacterial analogs which 
selectively inhibit DAP pathway shall be more effective and less toxic 
to mammals. This type of specific drug discovery approach will open 
several opportunities and methodologies to treat diseases using 
antimicrobial therapy. These drugs shall be able to sustain for a 
longer time in the market. 
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ABBREVIATIONS 
ASADH - Aspartate semialdehyde dehydrogenase 
DHDPS-Dihydrodipicolinate synthase 
DHDPR - Dihydrodipicolinate reductase  
THPC-NST - Tetrahydrodipicolinate N-succinyltransferase  
NSDAP-AT - N-succinyldiaminopimelate aminotransferase  
SDAP-DS - Succinyldiaminopimelate desuccinylase  
THDP-NAT - Tetrahydrodipicolinate N-acetyltransferase  
ATA - Aminotransferase A  
NAD-DAC - N-acetyldiaminopimelate deacetylase  
LL-DAP-AT - Diaminopimelate aminotransferase  
DAPE - Diaminopimelate epimerase  
DAPDC - Diaminopimelate decarboxylase  
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